Literature DB >> 32120300

Structure-based virtual screening of influenza virus RNA polymerase inhibitors from natural compounds: Molecular dynamics simulation and MM-GBSA calculation.

Zhe Jin1, Ying Wang1, Xiao-Fei Yu1, Qi-Qi Tan1, Shi-Shao Liang1, Tai Li1, Hong Zhang2, Pang-Chui Shaw3, Jian Wang4, Chun Hu5.   

Abstract

The resistances of matrix protein 2 (M2) protein inhibitors and neuraminidase inhibitors for influenza virus have attracted much attention and there is an urgent need for new drug. The antiviral drugs that selectively act on RNA polymerase are less prone to resistance and possess fewer side effects on the patient. Therefore, there is increased interest in screening compounds that can inhibit influenza virus RNA polymerase. Three natural compounds were found by using molecular docking-based virtual screening, which could bind tightly within the polymerase acidic protein-polymerase basic protein 1 (PA-PB1) subunit of influenza virus polymerase. Firstly, their drug likeness properties were evaluated, which showed that the hepatotoxicity values of all the three compounds indicating they had less or no hepatotoxicity, and did not have the plasma protein biding (PPB) ability, the three compounds needed to be modified in some aspects, like bulky molecular size. The stability of the complexes of PA-hits was validated through molecular dynamics (MD) simulation, revealing compound 2 could form more stable complex with PA subunit. The torsional conformations of each rotatable bond of the ligands in PA subunit were also monitored, to investigate variation in the ligand properties during the simulation, compound 3 had fewer rotatable bonds, indicating that the molecule had stronger rigidity. The bar charts of protein-ligand contacts and contacts over the course of trajectory showed that four key residues (Glu623, Lys643, Asn703 and Trp706) of PA subunit that participated in hydrogen-bond, water bridge and hydrophobic interactions with the hit compounds. Finally, the binding free energy and contributed energies were calculated by using MM-GBSA method. Out of the three compounds, compound 1 showed the lowest total binding free energy. Among all the interactions, the contribution of the covalent binding and the van der Waals energy were more than other items, compound 1 formed more stable hydrogen bonds with the residues of PA subunit binding pocket. This study smoothed the path for the development of novel lead compounds with improved binding properties, high drug likeness, and low toxicity to humans for the treatment of influenza, which provided a good basis for further research on novel and effective influenza virus PA-PB1 interaction inhibitors.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Drug likeness; Influenza virus; Molecular dynamics simulations; Protein-protein interaction inhibitor; Virtual screening

Mesh:

Substances:

Year:  2020        PMID: 32120300     DOI: 10.1016/j.compbiolchem.2020.107241

Source DB:  PubMed          Journal:  Comput Biol Chem        ISSN: 1476-9271            Impact factor:   2.877


  9 in total

1.  Optimizing the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach.

Authors:  Bhagyashri Chaudhari; Harun Patel; Snehal Thakar; Iqrar Ahmad; Deepali Bansode
Journal:  In Silico Pharmacol       Date:  2022-07-02

2.  Urea-thiazole/benzothiazole hybrids with a triazole linker: synthesis, antimicrobial potential, pharmacokinetic profile and in silico mechanistic studies.

Authors:  Nisha Poonia; Kashmiri Lal; Ashwani Kumar; Anil Kumar; Srikanta Sahu; Anurag T K Baidya; Rajnish Kumar
Journal:  Mol Divers       Date:  2021-10-20       Impact factor: 3.364

3.  Optimizing Bedaquiline for cardiotoxicity by structure based virtual screening, DFT analysis and molecular dynamic simulation studies to identify selective MDR-TB inhibitors.

Authors:  Iqrar Ahmad; Harsha Jadhav; Yashodeep Shinde; Vilas Jagtap; Rukaiyya Girase; Harun Patel
Journal:  In Silico Pharmacol       Date:  2021-03-23

4.  In silico structural elucidation of the rabies RNA-dependent RNA polymerase (RdRp) toward the identification of potential rabies virus inhibitors.

Authors:  Duangnapa Kiriwan; Kiattawee Choowongkomon
Journal:  J Mol Model       Date:  2021-05-24       Impact factor: 1.810

5.  In silico identification and study of potential anti-mosquito juvenile hormone binding protein (MJHBP) compounds as candidates for dengue virus - Vector insecticides.

Authors:  Chimaobi James Ononamadu; Mohnad Abdalla; Godwin Okwudiri Ihegboro; Jin Li; Tajudeen Alowonle Owolarafe; Timothy Datit John; Qiang Tian
Journal:  Biochem Biophys Rep       Date:  2021-11-30

6.  Molecular Docking and Virtual Screening of an Influenza Virus Inhibitor That Disrupts Protein-Protein Interactions.

Authors:  Yixin Ren; Sihui Long; Shuang Cao
Journal:  Viruses       Date:  2021-11-05       Impact factor: 5.048

7.  A Comprehensive In Silico Exploration of Pharmacological Properties, Bioactivities, Molecular Docking, and Anticancer Potential of Vieloplain F from Xylopia vielana Targeting B-Raf Kinase.

Authors:  Syed Shams Ul Hassan; Syed Qamar Abbas; Fawad Ali; Muhammad Ishaq; Iqra Bano; Mubashir Hassan; Hui-Zi Jin; Simona G Bungau
Journal:  Molecules       Date:  2022-01-28       Impact factor: 4.411

8.  Identification of novel natural drug candidates against BRAF mutated carcinoma; An integrative in-silico structure-based pharmacophore modeling and virtual screening process.

Authors:  F A Dain Md Opo; Ahad Amer Alsaiari; Mohammad Habibur Rahman Molla; Md Afsar Ahmed Sumon; Khaled A Yaghmour; Foysal Ahammad; Farhan Mohammad; Jesus Simal-Gandara
Journal:  Front Chem       Date:  2022-10-04       Impact factor: 5.545

9.  QSAR, molecular docking and ADMET properties in silico studies of novel 4,5,6,7-tetrahydrobenzo[D]-thiazol-2-Yl derivatives derived from dimedone as potent anti-tumor agents through inhibition of C-Met receptor tyrosine kinase.

Authors:  Ossama Daoui; Souad Elkhattabi; Samir Chtita; Rachida Elkhalabi; Hsaine Zgou; Adil Touimi Benjelloun
Journal:  Heliyon       Date:  2021-07-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.